Month: September 2026

– Partnership will introduce NeuroSigma’s second-generation Monarch eTNS^® System to Firefly’s nationwide network of Evoke™ clinicians –

– Collaboration brings together an FDA-cleared pediatric ADHD treatment and Firefly’s objective brain-function assessment platform and AI-driven ADHD biomarker research –

– Monarch offers an at-home, non-medication treatment option for eligible children ages 7 through 12 ––

KENMORE, N.Y. and LOS ANGELES, Sept. 25, 2026 (GLOBE NEWSWIRE) — Firefly Neuroscience, Inc. (“Firefly”) (NASDAQ: AIFF), an artificial intelligence (“AI”) company advancing precision neuroscience, and NeuroSigma, Inc. (“NeuroSigma”), a bioelectronic medical device company, today announced a strategic partnership to expand clinician awareness of and access to NeuroSigma’s Monarch eTNS^® System through Firefly’s growing nationwide network of Evoke™ clinician customers.

The Monarch eTNS^® System is the first non-drug treatment for pediatric attention-deficit/hyperactivity disorder (“ADHD”) cleared by the U.S. Food and Drug Administration (“FDA”). Under the partnership, Firefly will introduce the Monarch device to psychiatry, neurology and behavioral health practices that use its FDA 510(k)-cleared, AI-powered Evoke™ EEG/ERP platform.

The collaboration brings together complementary technologies designed to address two significant needs in pediatric ADHD care: access to objective information about brain function and availability of a non-medication treatment option for eligible patients.

According to a 2024 study published in the Journal of Clinical Child & Adolescent Psychology, approximately one in nine U.S. children has received an ADHD diagnosis, representing an estimated 7.1 million children. And among the approximately 6.5 million children with current ADHD, nearly one-third received no ADHD-specific treatment.¹ At the same time, many families are seeking alternatives to stimulant medication for their children.²^, ³

“This partnership represents an important step toward a more objective and personalized approach to pediatric ADHD care,” said Greg Lipschitz, Chief Executive Officer of Firefly. “Clinicians need better tools to understand how an individual patient’s brain is functioning, more treatment options from which to choose and objective ways to evaluate changes over time. By introducing NeuroSigma’s FDA-cleared, non-drug therapy to our Evoke clinician network, we are connecting measurement-driven practices with an important treatment option for eligible children and their families.”

Firefly’s Evoke™ platform combines quantitative electroencephalography (“qEEG”) and event-related potential (“ERP”) testing with AI-powered analytics. Drawing upon Firefly’s proprietary database of more than 200,000 EEG/ERP brain scans, Evoke™ provides clinicians with objective information about individual brain function, including in patients whose symptoms may overlap across multiple conditions, and enables clinicians to track changes over time.

In March 2026, Firefly announced the discovery of EEG/ERP biomarkers, identified using data collected through Evoke™, that may help differentiate among the three ADHD presentations: predominantly inattentive, predominantly hyperactive-impulsive and combined. Subject to further research and validation, Firefly believes these findings could ultimately help clinicians better match patients with appropriate treatment approaches and objectively monitor their response to intervention.

The prescription-only Monarch eTNS^® System is a palm-sized device that delivers mild external trigeminal nerve stimulation (eTNS) through a small adhesive patch placed on a child’s forehead while the child sleeps. It is FDA-cleared as a monotherapy for children ages 7 through 12 with ADHD who are not currently taking prescription ADHD medication.

NeuroSigma commenced U.S. sales of its second-generation Monarch device in July 2026, following the development of a waitlist comprising more than 1,500 patients, caregivers and healthcare providers. In September, the company expanded payment options for families, including third-party installment plans.

“For too long, we have relied on symptom checklists and traditional evaluations alone to understand a child’s brain,” said Lauren Hernandez, M.D., a board-certified pediatrician with advanced certification in genomic medicine, and Chief Medical Officer of the pediatric program for NuWell Medicine. “Advanced qEEG technology, such as Evoke™, allows us to see how a child’s brain is actually functioning in real time, giving us a deeper understanding of attention, learning, emotional regulation, and overall neurological health. This technology helps identify the unique patterns behind challenges often labeled as ADHD, while also revealing when symptoms may be driven by anxiety, sensory processing differences, autonomic nervous system dysregulation, or other underlying factors. By understanding how the brain, gut, and autonomic nervous system work together, we can create more personalized and effective roadmaps that support resilience, health, and lifelong success. Evoke™ provides valuable insights that can help validate the need for medication when appropriate, while also helping families avoid unnecessary treatment when the root cause lies elsewhere. We are also excited about emerging tools, such as the Monarch eTNS^® System, which offer new opportunities to support children with ADHD and autism. For the first time, we have objective tools to measure progress and improvement over time, aligning perfectly with the Reformative Medicine approach of identifying what’s off balance, optimizing function, and restoring balance across the body’s interconnected systems.”

Under the agreement, Firefly will introduce the Monarch eTNS^® System to its Evoke™ clinician customers and support clinician education regarding the therapy. NeuroSigma will provide clinical training, prescribing support and product fulfillment through its specialty pharmacy partner.

“Firefly has built a network of clinicians who are already embracing a more objective, measurement-driven approach to brain health,” said Colin Kealey, M.D., President and Chief Executive Officer of NeuroSigma. “These clinics are well positioned to evaluate innovative treatment options for children and families seeking an alternative to medication. With our second-generation Monarch device now shipping and expanded payment options available, this partnership gives us an efficient pathway to educate more clinicians and broaden access to the first FDA-cleared, non-drug treatment for pediatric ADHD.”

Sources

¹ Danielson ML, Claussen AH, Bitsko RH, Katz SM, Newsome K, Blumberg SJ, Kogan MD, Ghandour R. ADHD Prevalence Among U.S. Children and Adolescents in 2022: Diagnosis, Severity, Co-Occurring Disorders, and Treatment. J Clin Child Adolesc Psychol. 2024 May-Jun;53(3):343-360. doi: 10.1080/15374416.2024.2335625. Epub 2024 May 22. PMID: 38778436; PMCID: PMC11334226.

² Lu SV, Leung BMY, Bruton AM, Millington E, Alexander E, Camden K, Hatsu I, Johnstone JM, Arnold LE. Parents’ priorities and preferences for treatment of children with ADHD: Qualitative inquiry in the MADDY study. Child Care Health Dev. 2022 Sep;48(5):852-861. doi: 10.1111/cch.12995. Epub 2022 Mar 25. PMID: 35244227; PMCID: PMC10215012.

³ Drechsler R, Brem S, Brandeis D, Grünblatt E, Berger G, Walitza S. ADHD: Current Concepts and Treatments in Children and Adolescents. Neuropediatrics. 2020 Oct;51(5):315-335. doi: 10.1055/s-0040-1701658. Epub 2020 Jun 19. PMID: 32559806; PMCID: PMC7508636.

About NeuroSigma

NeuroSigma is a bioelectronic medical device company based in Los Angeles, California. Its lead product, the Monarch eTNS^® System, is the first non-drug treatment for pediatric ADHD cleared by the FDA. NeuroSigma is also investigating the Monarch eTNS^® System in additional neurodevelopmental and neurological indications, including autism spectrum disorder, learning disabilities and drug-resistant epilepsy, for which the FDA has granted Breakthrough Device Designation; these pipeline indications are investigational and not FDA-cleared.

For more information, visit www.neurosigma.com and www.monarch-etns.com.

About Firefly Neuroscience

Firefly Neuroscience, Inc. (NASDAQ: AIFF) is an Artificial Intelligence (“AI”) company advancing precision neuroscience, applying AI and large-scale electrophysiological data to give clinicians a more complete, objective picture of how an individual patient’s brain is functioning. Firefly’s proprietary database consists of over 200,000 EEG/ERP brain scans, which the Company believes to be the world’s largest known standardized EEG/ERP repository. Firefly’s EEG-based, AI-driven, and FDA-510(k)-cleared Evoke™ System is designed to support diagnostic and treatment monitoring methods for conditions such as depression, dementia, anxiety disorders, concussions, ADHD, and PTSD.

Please visit www.fireflyneuro.com for more information.

Forward-Looking Statements

Certain statements in this press release may constitute “forward-looking statements” for purposes of the federal securities laws concerning Firefly, including statements regarding the anticipated benefits, scope, and results of the collaboration between Firefly and NeruSigma, statements regarding NeruSigma’s business, business, product and commercial plans; Firefly’s ADHD biomarker research and product development; and statements relating to Firefly’s management team’s expectations, hopes, beliefs, intentions, or strategies regarding the future. In addition, any statements that refer to projections, forecasts or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking statements. The words “anticipate,” “believe,” “contemplate,” “continue,” “could,” “estimate,” “expect,” “intends,” “may,” “might,” “plan,” “possible,” “potential,” “predict,” “project,” “should,” “will,” “would” and similar expressions may identify forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking. These forward-looking statements are based on current expectations and beliefs concerning future developments and their potential effects. There can be no assurance that future developments affecting Firefly will be those that have been anticipated. These forward-looking statements involve a number of risks, uncertainties (some of which are beyond Firefly’s control) and other assumptions that may cause actual results or performance to be materially different from those expressed or implied by these forward-looking statements. These risks and uncertainties include, but are not limited to, those factors described under the heading “Risk Factors” in the reports and other filings of Firefly with the Securities and Exchange Commission. Should one or more of these risks or uncertainties materialize, or should any of Firefly’s assumptions prove incorrect, actual results may vary in material respects from those projected in these forward-looking statements. It is not possible to predict or identify all such risks. Forward-looking statements included in this press release only speak as of the date they are made, and Firefly does not undertake any obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as may be required under applicable securities laws.

Important Safety Information

The Monarch eTNS^® System is available by prescription only. It is indicated for the treatment of pediatric ADHD as a monotherapy for patients ages 7 through 12 who are not currently taking prescription ADHD medication and is intended for home use during sleep under the supervision of a caregiver. Monarch should not be used by patients with an implanted cardiac or neurostimulation system or an implanted metallic or electronic device in the head. Do not apply the device to the neck or chest, do not use it in the bath or shower, and do not use it in the presence of electrical monitoring equipment such as cardiac monitors. Apply the patch only to healthy, clean, intact skin. The most commonly reported side effects are drowsiness, increased appetite, trouble sleeping, teeth clenching, headache, and fatigue. Talk with your child’s clinician about whether Monarch is right for your child.

For complete safety information, see the Instructions for Use.

Investor & Media Contacts

For Firefly
Stephen Kilmer
(646) 274-3580
stephen.kilmer@fireflyneuro.com

For NeuroSigma
Colin Kealey, M.D.
President and Chief Executive Officer
ckealey@neurosigma.com

Martin Bech Holte, primary insider and board member of SalMar ASA, has on 25 September 2026 acquired 2,000 shares in SalMar ASA at a price of NOK 565 per share. After the transaction, Martin Bech Holte owns 3,200 shares in SalMar.

Please see attached notification form in accordance with the Market Abuse Regulation article 19.

This information is subject of the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Trading Act and the Market Abuse Regulation Article 19.

Attachment

• PDMR form – Martin Bech Holte

To Nasdaq Copenhagen A/S	25 September 2026
	Announcement no. 82/2026

Fixing of Coupon Interest Rate

Interest rate for Jyske Realkredit’s:

Series BRF454BOA 38 with ISIN DK0009361628 has per 1 October 2026 and until and including 1 April 2027 been set at 3.84 % p.a.

Series BRF154B 38 with ISIN DK0009361701 has per 1 October 2026 and until and including 1 April 2027 been set at 3.84 % p.a.

Series BRF154E 41 with ISIN DK0009366932 has per 1 October 2026 and until and including 1 April 2027 been set at 3.49 % p.a.

Series BRF454EOA 41 with ISIN DK0009367070 has per 1 October 2026 and until and including 1 April 2027 been set at 3.49 % p.a.

Series 422.E.OA Cb3.ju27 RF with ISIN DK0009412207 has per 1 October 2026 and until and including 1 January 2027 been set at 2.91 % p.a.

Series G-422.E.OA Cb3.ju27 RF with ISIN DK0009412397 has per 1 October 2026 and until and including 1 January 2027 been set at 2.89 % p.a.

Series 422.B.OA Cb3.ju27 RF with ISIN DK0009412470 has per 1 October 2026 and until and including 1 January 2027 been set at 3.00 % p.a.

Series G422.E.OA Cb3.ju27 RF with ISIN DK0009414682 has per 1 October 2026 and until and including 1 January 2027 been set at 2.76 % p.a.

Series 422.E.OA Cb3.ju28 RF with ISIN DK0009414765 has per 1 October 2026 and until and including 1 January 2027 been set at 2.79 % p.a.

Series 422.E.OA Cb3.ju29 RF with ISIN DK0009417198 has per 1 October 2026 and until and including 1 January 2027 been set at 2.89 % p.a.

Series G422.E.OA Cb3 ju29 RF with ISIN DK0009417271 has per 1 October 2026 and until and including 1 January 2027 been set at 2.85 % p.a.

Series 422.E.OA Cb3.ju30 RF with ISIN DK0009419137 has per 1 October 2026 and until and including 1 January 2027 been set at 2.62 % p.a.

Series SNP322.ap.28 with ISIN DK0009417008 has per 1 October 2026 and until and including 1 January 2027 been set at 3.23 % p.a.

Questions may be addressed to Christian Bech-Ravn, tel. (+45) 89 89 92 25.

Yours sincerely,

Jyske Realkredit

Please observe that the Danish version of this announcement prevails.

www.jyskerealkredit.com

25 September 2026

LSE Code: 3EUS

WISDOMTREE MULTI ASSET ISSUER PUBLIC LIMITED COMPANY
(a public company incorporated with limited liability in Ireland)
WISDOMTREE EURO STOXX 50® 3X DAILY SHORT SECURITIES
ISIN: XS3306517502

RESULTS OF MEETING OF THE ETP SECURITYHOLDERS

WisdomTree Multi Asset Issuer Public Limited Company (the “Issuer”) wishes to announce that the Extraordinary Resolution regarding the reduction in the principal amount of the WisdomTree EURO STOXX 50® 3x Daily Short Securities (the “Affected Securities”) from EUR 2.8 to EUR 0.28, as set out in a notice to holders of the Affected Securities dated 4 August 2026, was passed at an adjourned meeting of the holders of the Affected Securities held at 11am on 25 September 2026.

As a result, the Deed of Amendment has been duly executed by the Issuer, the Manager and the Trustee to put the proposed amendments to the Trust Deed into effect from 25 September 2026.

Company Concentrates Its System-of-Systems Thesis on Three Pillars: The Quantum Antenna, One-Way Attack / Interceptor Drones, and the MAHCA Operating System — Anchored at Its Bridgeport, Connecticut Manufacturing Facility as Quantum Cyber Advances Toward Commercialization

Norwalk, CT, Sept. 25, 2026 (GLOBE NEWSWIRE) — Quantum Cyber N.V. (Nasdaq: QUCY) (“Quantum Cyber” or the “Company”), a Nasdaq-listed autonomous defense technology company assembling an AI-powered System-of-Systems platform for drone warfare, counter-UAS, and border security applications, today announced a sharpened strategic focus, reframing the Company’s thesis for the era of GPS-deficient, autonomous warfare, and presented its updated Corporate Investor Presentation. The full presentation is available at https://quantum-cyber.ai/investors/presentations.

The presentation consolidates the Company’s refocused strategy, technology portfolio, and manufacturing footprint into a single investor-facing document. Key sections include:

Warfare, Reimagined for the Quantum Era. Quantum Cyber’s strategy is now organized around a single thesis: the next war will be fought in environments where GPS fails, where electronic warfare dominates, and where mass-produced attritable autonomy decides the outcome. The Company’s exclusively-licensed quantum antenna technology, executed with Project LightShift, Inc. on June 11, 2026, is positioned as the differentiating layer of the platform — an unjammable, magnetic-field-based navigation, communications and energy-capture reference for autonomous systems operating in contested environments where satellite-guided precision has become a single point of failure.

Concentration on Three Product Pillars. Quantum Cyber has narrowed its System-of-Systems platform focus to three product pillars: one-way attack drones and interceptors; the quantum antenna, invented by Dr. Wolf Kohn, providing power, communications and navigation in a single component; and the MAHCA operating system, the Multiple Agent Hybrid Control Architecture that orchestrates coordinated swarm behavior across autonomous platforms. Maritime programs and other exploratory initiatives have been de-emphasized so the Company can concentrate capital, engineering, and commercial resources on near-term commercialization.

Total Addressable Market — Four Target Applications. Quantum Cyber’s commercial strategy is now focused on Border Patrol, Warfare / Defense UAS, Law Enforcement, and the GPS-Alternative / Quantum Navigation category, the latter validated by parallel programs at Honeywell and Northrop Grumman.

Ukraine Doctrine and the $5,000 Drone. The Company’s platforms are engineered for the attritable-autonomy economics validated in the Ukraine conflict, where $5,000-class drones have neutralized multi-million-dollar armored platforms in electronic-warfare-saturated environments within 20 km of the front line.

Leadership Depth. Dr. Wolf Kohn, Chief Scientist and Head of Quantum — inventor of the licensed quantum antenna technology; former Engineer of the Year at Lockheed Martin, Boeing and NASA; prior work with DARPA; and a former MIT professor and graduate. Tzvi Lev, Head of Middle East Sales — a high-ranking reserves officer leading the Company’s Middle East and Gulf commercial channel. Dennis Schnur, Head of U.S. Sales — a U.S. Army veteran (77th ARCOM) with 60+ years leading large-scale U.S. distribution operations, anchoring the Company’s U.S. commercial build-out. The Company’s Ukrainian engineering team continues to lead product development, contributing five years of active-electronic-warfare combat experience.

Made in America — Vertically Integrated. Quantum Cyber’s manufacturing strategy is anchored at its owned ~50,000 sq ft facility in Bridgeport, Connecticut, acquired July 16, 2026. An 80-unit 3D printing drone production farm was installed and became operational on August 31, 2026. Ongoing equipment procurement includes motors, CNC machinery for airframes, routers and propellers, and injection-molding capacity, supported by a High-Density MIL-STD Power Architecture designed for low-cost, scalable drone assembly. Targeted annual production capacity of 100,000 drones represents forward-looking management projections and is not current operational capacity.

Policy Tailwinds. Executive Order 14307 establishes American drone dominance as an explicit national security and industrial priority, and the current administration’s Buy American procurement mandate and tariff regime carry a structural, tariff-advantaged position for U.S.-based defense manufacturers such as Quantum Cyber. The Trump Administration is seeking approximately $55 billion for drone and autonomous warfare programs in the fiscal year 2027 defense budget.

“The next war will be fought in GPS-denied environments by autonomous systems at scale, and we have concentrated our platform, our team, and our manufacturing footprint around that reality,” said David Lazar, Chief Executive Officer of Quantum Cyber. “Quantum navigation, interceptors, MAHCA, and a U.S. factory — that is the strategy, and every dollar of capital and every hire from here forward is measured against it.”

About Quantum Cyber N.V.
Quantum Cyber N.V. (Nasdaq: QUCY) is assembling an AI-powered, quantum-accelerated System-of-Systems autonomous defense platform that integrates drone warfare, counter-UAS, autonomous naval mine countermeasures, EMP shielding, anti-drone ammunition, command-and-control, and quantum antenna applications under a single Nasdaq-listed company. The Company acquires, licenses, and develops combat-proven autonomous technologies, deploying them as a coordinated, multi-domain portfolio across air, land, and sea. For more information, visit www.quantum-cyber.ai.

Forward-Looking Statements
Certain statements made in this press release are “forward-looking statements” within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements may be identified by the use of words such as “anticipate,” “believe,” “expect,” “estimate,” “plan,” “outlook,” and “project” and other similar expressions that predict or indicate future events or trends or that are not statements of historical matters. Such forward-looking statements relate to, among other things, management’s strategic focus; the anticipated development, integration, and commercialization of the Company’s quantum antenna, interceptor, one-way attack, and MAHCA operating system technologies; the exclusive Intellectual Property License Agreement with Project LightShift, Inc. dated June 11, 2026; targeted total addressable markets and target applications; targeted annual production capacity of 100,000 drones and other manufacturing plans and equipment procurement at the Bridgeport, Connecticut facility; tariff, policy, and budget tailwinds, including the Fiscal Year 2027 defense budget request; and the Company’s broader business strategy and technology pipeline. These forward-looking statements reflect the current analysis of existing information and are subject to various risks and uncertainties. Due to known and unknown risks, actual results may differ materially from the Company’s expectations or projections. The following factors, among others, could cause actual results to differ materially from those described in these forward-looking statements: (i) the failure to meet development, prototype, or manufacturing milestones; (ii) the failure of Project LightShift, Inc. to perform its obligations under the License Agreement; (iii) changes in applicable laws, regulations, or trade and procurement policy; (iv) an inability to successfully pursue new initiatives; and (v) other risks and uncertainties discussed from time to time in other reports and public filings with the Securities and Exchange Commission (the “SEC”) by the Company. The Company’s SEC filings are available publicly on the SEC’s website at www.sec.gov. Any forward-looking statement made in this press release is based only on information currently available to the Company and speaks only as of the date on which it is made. The Company undertakes no obligation to publicly update any forward-looking statement, whether written or oral, except as required by law.

Investor Relations Contact
Arx Investor Relations
North American Equities Desk
qucy@arxhq.com

TORONTO and SINGAPORE, Sept. 25, 2026 (GLOBE NEWSWIRE) — Abaxx Technologies Inc. (TSX:ABXX)(OTCQX:ABXXF) (“Abaxx” or the “Company”), a financial software and market infrastructure company, majority shareholder of Abaxx Singapore Pte Ltd., the owner of Abaxx Commodity Exchange and Clearinghouse (individually, “Abaxx Exchange” and “Abaxx Clearing”), today announced that Abaxx Exchange’s Gold Singapore (GKS) futures contract has been named Best Innovation by an Exchange or Clearing House at the 2026 FOW Asia Pacific Awards.

The FOW Asia Pacific Awards recognize outperformance and innovation by firms and individuals across the Asian derivatives industry. Award winners were chosen by an independent panel of experts from throughout the industry.

Comments from the judges included: “In yet another year of volatility for the commodity sector, this award was based on the strides Abaxx has made in launching products aimed at making a meaningful contribution to the market and indeed in creating more accurate regional benchmarks. The FOW team congratulates Abaxx on this well-deserved recognition.”

“It is an honor to receive this award from FOW,” said Russell Robertson, Chief Business Development Officer at Abaxx Exchange. “We launched Gold Singapore futures in June 2025 in anticipation of the bullion market’s growing need for reliable regional price discovery for gold kilobars. As Hong Kong and Singapore grow as Asian bullion centers, GKS is well positioned to become the benchmark for the price of gold in Singapore and support arbitrage across Asia. We’re grateful to our growing network of market participants for their confidence in Abaxx gold futures as we contribute to Singapore’s emergence as a global precious metals hub.”

The award follows Abaxx Exchange’s recognition as Newcomer of the Year at the 2026 Energy Risk Awards in May.

About Abaxx Technologies
Abaxx Technologies Inc. (TSX: ABXX | OTCQX: ABXXF) is building Smarter Markets: markets empowered by better tools, better benchmarks, and better technology to drive market-based solutions to the biggest challenges we face as a society, including the energy transformation and the transition to an AI-augmented economy.

In addition to developing and deploying financial technologies that make communication, trade, and transactions easier and more secure, Abaxx is the majority shareholder of Abaxx Singapore, the owner of Abaxx Exchange and Abaxx Clearing, parent company of wholly owned subsidiaries Abaxx Spot and Adaptive Infrastructure, and founder and creator of Abaxx Labs and the SmarterMarkets™ podcast.

For more information, visit investors.abaxx.tech, abaxx.exchange, abaxxspot.com and smartermarkets.media

For more information about this press release, please contact:

Steve Fray, CFO
Tel: +1 647-490-1590

Media Inquiries
Tara Hayes
Email: tara@abaxx.tech

Investor Inquiries
Tel: +1 246 271 0082
E-mail: ir@abaxx.tech

Cautionary Statement Regarding Forward-Looking Information

This press release includes certain “forward-looking statements” and “forward-looking information” (collectively, “forward-looking statements”) within the meaning of applicable Canadian and United States securities laws. All statements other than statements of historical fact are forward-looking statements. Forward-looking statements are often, but not always, identified by the use of words such as “believe”, “anticipate”, “estimate”, “project”, “intend”, “expect”, “may”, “will”, “plan”, “should”, “would”, “could”, “target”, “purpose”, “goal”, “objective”, “ongoing”, “potential”, “likely” or the negative thereof or similar expressions.

In particular, this press release contains forward-looking statements including, without limitation, Abaxx’s objectives, future plans, the adoption of GKS as a benchmark for the price of gold in Singapore and support arbitrage across Asia, the growth of Abaxx’s network of market participants and Abaxx’s contribution to Singapore as a global precious metals hub. Forward-looking statements are based on the reasonable assumptions, estimates, analyses and opinions of management made in light of its experience and its perception of trends, current conditions and expected developments, as well as other factors that management believes to be relevant and reasonable in the circumstances at the date that such statements are made, but which may prove to be incorrect. Such factors impacting forward-looking information include, among others: risks relating to the global economic climate; the risk that trading volume, average daily volume, and open interest on Abaxx Exchange may not continue to grow, or may decline, if the liquidity-related credits provided under Abaxx’s market maker and liquidity provider programs are reduced, discontinued, or otherwise changed, or if market participants who currently trade on Abaxx Exchange in connection with such programs do not continue to trade, or do not increase their trading activity, independently of such programs; dilution; Abaxx’s limited operating history; future capital needs and uncertainty of additional financing; the competitive nature of the industry; currency exchange risks; the need for Abaxx to manage its planned growth and expansion; the effects of product development and need for continued technology change; protection of proprietary rights; the effect of government regulation and compliance on Abaxx and the industry; acquiring and maintaining regulatory approvals for Abaxx’s products and operations; the ability to list Abaxx’s securities on stock exchanges in a timely fashion or at all; network security risks; the ability of Abaxx to maintain properly working systems; reliance on key personnel; global economic and financial market deterioration impeding access to capital or increasing the cost of capital; volatile securities markets impacting security pricing unrelated to operating performance. In addition, particular factors and assumptions which could impact future results of the business of Abaxx include but are not limited to: Abaxx’s assumption that trading volume and liquidity on Abaxx Exchange will continue to develop over time, independently of its market maker and liquidity provider programs; the failure of energy, commodity markets and collateral use cases to develop according to the expectations of Abaxx; assumptions related to the actions of political actors in foreign jurisdiction and related risks; the continued protection of Abaxx’s intellectual property rights; contractual risk; third-party risk; clearinghouse risk; malicious actor risks; third-party software license risk; system failure risk; dependence of technical infrastructure; changes in global weather patterns; changes in the price of commodities, capital market conditions, restrictions on labor and international travel and supply chains, and the risk factors identified in the Company’s most recent management’s discussion and analysis filed on SEDAR+. Abaxx has also assumed that no significant events occur outside of Abaxx’s normal course of business.

Abaxx cautions that the foregoing list of material factors is not exhaustive. In addition, although Abaxx has attempted to identify important factors that could cause actual results to differ materially, there may be other factors that cause results not to be as anticipated, estimated, or intended. When relying on forward-looking statements and information to make decisions, investors and others should carefully consider the foregoing factors and other uncertainties and potential events. Abaxx has assumed that the material factors referred to in the previous paragraphs will not cause such forward-looking statements and information to differ materially from actual results or events. However, the list of these factors is not exhaustive and is subject to change and there can be no assurance that such assumptions will reflect the actual outcome of such items or factors. The forward-looking statements and information contained in this press release represents the expectations of Abaxx as of the date of this press release and, accordingly, is subject to change after such date. Abaxx undertakes no obligation to update or revise any forward-looking statements and information, whether as a result of new information, future events or otherwise, except as required by law. Accordingly, readers are cautioned not to place undue reliance on these forward-looking statements and information. Neither the Toronto Stock Exchange nor any other securities exchange or regulatory authority accepts responsibility for the adequacy or accuracy of this release.

ROCKVILLE, Md., Sept. 25, 2026 (GLOBE NEWSWIRE) — X-Energy, Inc. (Nasdaq: XE) (“X-energy” or “the Company”), a leading developer of advanced nuclear reactors and fuel technology, today announced that Joel Duling will retire from full-time executive leadership as president of TRISO-X, its wholly-owned nuclear fuels subsidiary, effective November 20, 2026. After more than four decades of exemplary leadership across nuclear operations, manufacturing, and program management, including leading TRISO-X through several significant milestones in its commercial development and construction, Duling has decided to step back from day-to-day leadership responsibilities to devote more time to his health, family, and personal priorities.

Duling will remain a part-time employee of X-energy as a senior advisor to Chief Executive Officer J. Clay Sell, supporting the company’s strategic fuel partnerships and fuel supply chain development, as well as the transition to the next president of TRISO-X. Following Duling’s transition, Jason Hatfield, TRISO-X vice president and chief of staff, will assume interim leadership of TRISO-X, while X-energy’s Global Chief Operating Officer Dragan Popovic will continue to provide integration and oversight of the construction of the TX-1 fuel fabrication facility as part of the Advanced Reactor Demonstration Program. The Company is in the process of evaluating internal and external candidates for a permanent successor.

“Joel has been an extraordinary leader whose contributions have established a strong foundation for the future growth of TRISO-X,” said J. Clay Sell, CEO of X-energy. “Under his leadership, TRISO-X has built an exceptional team and established critical building blocks for the development of an unprecedented commercial advanced nuclear fuel supply chain. Out of complete respect for Joel, but with considerable initial reluctance, I have accepted Joel’s decision to devote more of his time to his health, family, and personal priorities, and I am personally grateful that he will continue to play a meaningful role within X-energy as a key strategic advisor.”

Under Duling’s leadership, TRISO-X has achieved several important milestones critical for continued growth. These include advancing construction of the first purpose-built commercial TRISO fuel fabrication facility in the United States, securing the first U.S. Nuclear Regulatory Commission license to commercially manufacture high-assay low-enriched uranium based TRISO fuel, and submitting the first advanced nuclear fuel fabricated for commercial use to enter irradiation testing at Idaho National Laboratory’s Advanced Test Reactor.

“It has been a true honor and a privilege to lead TRISO-X and work alongside such an exceptional team,” added Duling. “I am deeply proud of what this organization has accomplished and the foundation we have established for the future. I look forward to continuing to support this team and our mission through my new role at X-energy, and I have every confidence in the team’s ability to build on the progress we have made.”

TRISO-X continues to advance construction of TX-1, its state-of-the-art advanced nuclear fuel fabrication facility in Oak Ridge, Tennessee, recently marking the completion of vertical construction of the 214,000-square-foot facility. Construction has now moved to the next phase of work, including interior buildout, installation of fuel fabrication equipment, and continued construction of supporting facilities.

About X-energy
X-energy is a leading designer of advanced small modular nuclear reactors (“SMR”) and fuel technology developed to establish a new standard in clean, safe, reliable energy. X-energy’s intrinsically safe Xe-100 high-temperature gas-cooled reactor and TRISO-X particle fuel expand applications for nuclear technology, with commercial projects across grid, industrial, and AI. Together, X-energy’s technology drives enhanced safety, lower cost, faster construction timelines, and scalable deployment when compared with other SMRs and conventional nuclear. For more information, visit X-energy.com.

Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, which X-energy intends to be covered by the safe harbor provisions of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Words such as “assume,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “will,” “seek,” the negative of these words, or similar terms may identify forward-looking statements, but their absence does not mean a statement is not forward-looking. These include, but are not limited to, statements regarding the expected completion of TX-1; benefits of the Company’s Oak Ridge campus; expectations regarding the achievement of commercial scale manufacturing; ability to achieve a smooth transition; and expected continued success.

You should not rely on these forward-looking statements as predictions of future events. Actual results may differ materially due to a number of factors, including, but not limited to: delays, cost increases, or setbacks in the construction, licensing, or scaling of TX-1 and the Company’s fuel fabrication campus; changes, delays, or inability to obtain and maintain licenses or governmental approvals; supply chain and supplier constraints; risks associated with leadership and management transitions and the search for a permanent successor; and first-of-a-kind risks and the Company’s limited operating experience at intended scale, including latent design or operational issues. More information about potential risks is detailed under “Risk Factors” in X-energy’s Form 10-Q filed with the Securities and Exchange Commission (the “SEC”), and in subsequent SEC filings, available on X-energy’s Investor Relations website at https://investors.x-energy.com/ and on the SEC website at www.sec.gov. Any forward-looking statements herein are based on assumptions believed reasonable as of, and speak only as of, the date of this press release. Except as required by law, X-energy undertakes no obligation to update these statements as a result of new information or future events.

Contact

Robert McEntyre, Corporate Communications
media@x-energy.com
+1 240.673.6565

Patricia Gil, Investor Relations
+1 301.558.3040
investors@x-energy.com